CBMR publications and media appearances in May 2024

Media Appearances

---

Professor Juleen R. Zierath (Zierath Group)

Berlingske, 04/05/2024
'Hun forsker i, hvornår det er bedst at dyrke motion: Man kan få mere ud af træning på bestemt tidspunkt af dagen'

 The New York Times, 04/05/2924
'When Is the Best Time to Work Out?'

Berlingske, 05/05/2024
'Det er ikke lige meget, hvornår vi spiser, hvis vi vil undgå overvægt, fortæller forsker - mad feder mere på bestemt tidspunkt'

 The New York Times, 07/05/2024, Section D, page 7
'Pick an Exercise Option: Morning, Noon or Night'

 

Professor Jens Juul Holst (Juul Holst Group)

Ingeniøren, 31/05/2024, Section 1, page 20
'Sommerlæsning: På rundtur i tarmen og et stik i armen'

 

Professor Romain Barrès (Barrès Group)

Daily Record, 05/05/2024
'A father's diet 'plays key role in children's health' before they're even born'

 

Associate Professor Christoffer Clemmensen (Clemmensen Group)

TV2, 15/05/2024
'Ny vægttabsmedicin skal smugle molekyler ind i hjernen som en trojansk hest'

Videnskab.dk, 15/05/2024
'Danske forskere udvikler nyt vægttabsmiddel, som de tror kan overgå Wegovy'

 Avisen Danmark, 16/05/2024
'Banebrydende forskning: Næste generation af vægttabsmedicin er på vej'

Woman.dk, 16/05/2024
'Ny medicin kan føre til større vægttab end Wegovy - og virker ved at påvirke hjernen'

Berlingske, 16/05/2024
'Novo Nordisk har allerede skabt et »vidundermiddel«. Nu kan næste generation være på vej, og den »ser ud til at være meget effektiv«'

Dagens Pharma, 16/05/2024
'Ny generation af vægttabsmedicin på vej'

Medical Xpress, 16/05/2024
'Trojan Horse' weight loss drug found to be more effective than available therapies'

Politiken, 16/05/2024, Section 1, page 4
'Danske forskere laver kemisk nøgle, som måske kan give større vægttab end Wegovy og bedre behandling af Alzheimers'

Weekendavisen, 17/05/2024, Section 4, page 3
'Våbenkapløb: Wegovy 2.0'

Fastcompany.com, 17/05/2024
'Forget Ozempic: There could be an even more effective weight-loss drug on the way'

Kristeligt Dagblad, 18/05/2024, Section 2, page 9
'Næste generation af vægttabsmedicin er lige om hjørnet'

New York Post, 20/05/2024
'Better than Ozempic? ‘Very strong’ new weight loss drug is ‘so effective’'

Alt for damerne, 20/05/2024
'Mette var i et slanke-eksperiment, men ekspert slukkede hendes og manges drøm'

Illusteret Videnskab, 22/05/2024
'Ny vægttabsmedicin snyder hjernen med en trojansk hest af molekyler'

 

Associate Professor Atul Deshmukh (Deshmukh Group)

Nature, 01/05/2024
'Why is exercise good for you? Scientists are finding answers in our cells'

 

Postdoc Jens Lund (Clemmensen & Gerhart-Hines Group)

Berlingske, 25/05/2025
'De spiser løs og motionerer ikke, men tager aldrig på – og de kan være en del af løsningen på den stigende overvægt'

 

Associate Professor Jonas Treebak (Treebak Group)

South China Morning Post, 26/05/2024
'Harvard scientist behind Justin Bieber’s NAD therapy resigns, leaving China’s booming anti-ageing industry in hot water'

 

 

Publications

---

Barrès Group
Hjort L, et al. Epigenetics of the non-coding RNA nc886 across blood, adipose tissue and skeletal muscle in offspring exposed to diabetes in pregnancy. Clin Epigenetics. 2024 May 7;16(1):61. doi: 10.1186/s13148-024-01673-3.

 

Clemmensen, Deshmukh, Pers & Schwartz Groups
Petersen J, et al. GLP-1-directed NMDA receptor antagonism for obesity treatment. Nature. 2024 May;629(8014):1133-1141. doi: 10.1038/s41586-024-07419-8. Epub 2024 May 15.

 

Gerhart-Hines Group
Rausch N, et al. Cutting through dogma: a novel tool to dissect lactate biology. J Physiol. 2024 May 13. doi: 10.1113/JP286653. Epub ahead of print.

 

Guasch Group
Feng C, et al. Secular Trends in Adherence to Healthy Behaviors Among US Adults with Diabetes, 1999-2018. Am J Epidemiol. 2024 May 29:kwae090. doi: 10.1093/aje/kwae090. Epub ahead of print.

Tessier AJ, et al. Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death. JAMA Netw Open. 2024 May 1;7(5):e2410021. doi: 10.1001/jamanetworkopen.2024.10021.

 

Hansen Group
Hansen AL, et al. Low birthweight in patients with type 2 diabetes is associated with elevated risk of cardiovascular events and mortality. Diabetologia. 2024 May 22. doi: 10.1007/s00125-024-06170-z. Epub ahead of print.

Lin L, et al. Analysis of admixed Greenlandic siblings shows that the mean genotypic values for metabolic phenotypes differ between Inuit and Europeans. Genome Med. 2024 May 23;16(1):71. doi: 10.1186/s13073-024-01326-3.

Mas-Bermejo P, et al. Genetic risk score based on obesity-related genes and progression in weight loss after bariatric surgery: a 60-month follow- up study. Surg Obes Relat Dis. 2024 Apr 6:S1550-7289(24)00132-1. doi: 10.1016/j.soard.2024.04.002. Epub ahead of print.

Peña E, et al. Use of polygenic risk scores to assess weight loss after bariatric surgery: a 5-year follow-up study. J Gastrointest Surg. 2024 May 29:S1091-255X(24)00485-2. doi: 10.1016/j.gassur.2024.05.029. Epub ahead of print.

Wimmelmann CL, et al. Childhood adversity trajectories and weight status in young adult men: a register-based study including 359,783 Danish men. Int J Obes (Lond). 2024 May 30. doi: 10.1038/s41366-024-01540-4. Epub ahead of print.

 

Juul Holst Group
Kliim-Hansen V, et al. Gluco-metabolic response to exogenous oxytocin in totally pancreatectomized patients and healthy individuals. Peptides. 2024 May 22;179:171242. doi: 10.1016/j.peptides.2024.171242. Epub ahead of print.

Mantri A, et al. Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Nutrients. 2024 Apr 26;16(9):1300. doi: 10.3390/nu16091300.

Rix I, et al. Increased hepatic glucagon sensitivity in totally pancreatectomised patients. Eur J Endocrinol. 2024 Jun 5;190(6):446-457. doi: 10.1093/ejendo/lvae054.

Winther-Sørensen M, et al. Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study. Diabetologia. 2024 May 6. doi: 10.1007/s00125-024-06160-1. Epub ahead of print.

 

Loos Group
Hemerich D, et al. An integrative framework to prioritize genes in more than 500 loci associated with body mass index. Am J Hum Genet. 2024 Jun 6;111(6):1035-1046. doi: 10.1016/j.ajhg.2024.04.016. Epub 2024 May 15.

Hrytsenko Y, et al. Machine learning models for predicting blood pressure phenotypes by combining multiple polygenic risk scores. Sci Rep. 2024 May 30;14(1):12436. doi: 10.1038/s41598-024-62945-9.

Weng LC, et al. Meta-Analysis of Genome-Wide Association Studies Reveals Genetic Mechanisms of Supraventricular Arrhythmias. Circ Genom Precis Med. 2024 Jun;17(3):e004320. doi: 10.1161/CIRCGEN.123.004320. Epub 2024 May 28.

 

Merino Group
Billings LK, et al. Increased genetic risk for β-cell failure is associated with β-cell function decline in people with prediabetes. Diabetes. 2024 May 17:db230761. doi: 10.2337/db23-0761. Epub ahead of print.

 

Schéele Group
Talamonti E, et al. The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis. Mol Metab. 2024 Jul;85:101931. doi: 10.1016/j.molmet.2024.101931. Epub 2024 May 17.

Topics